Clinical Trial Update: A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update describes a study evaluating whether odronextamab combined with lenalidomide is safe and more effective than rituximab combined …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Odronextamab (odronextamab)
• Rituximab (rituximab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | Phase 3 | Status: RECRUITING